Lercanidipina Ratiopharm Italia (Lercanidipine Hydrochloride)

• Lercanidipine is a calcium channel blocker used to manage conditions that involve high arterial pressure.
• Hypertension: reduces systolic and diastolic blood pressure, helping to lower the risk of cardiovascular events.

• Lercanidipine selectively inhibits L‑type calcium channels in vascular smooth muscle cells. By blocking calcium influx, it prevents contraction of arterial smooth muscle, leading to vasodilation of peripheral arteries. The resulting decrease in systemic vascular resistance lowers arterial blood pressure without significant effect on heart rate or cardiac output.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Flushing: warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness: especially upon standing.
• Tiredness: general feeling of fatigue.
• Nasal congestion: blocked or runny nose.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure.
• Angio‑edema: rapid swelling of face, lips, or throat.
• Hepatic dysfunction: abnormal liver enzyme levels.
• Cardiac arrhythmia: irregular heart rhythm.
• Allergic reaction: rash, itching, or anaphylaxis.
• Myocardial infarction: rare occurrence of heart attack.

• Before initiating therapy with lercanidipine, consider the following safety measures.
• Pregnancy: avoid use unless clearly needed; discuss risks with a healthcare professional.
• Breastfeeding: assess benefit‑risk ratio; drug may pass into milk.
• Severe hepatic impairment: dose adjustment may be required.
• Concomitant use with strong CYP3A4 inhibitors: monitor for increased exposure.
• Elderly patients: start at low dose and titrate cautiously.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Lercanidipine can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma levels and increase risk of hypotension.
• Grapefruit juice: can markedly increase drug concentration.
• Other antihypertensives: additive blood‑pressure lowering effect may cause severe hypotension.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness.
• Diuretics: may enhance electrolyte disturbances.
• Beta‑blockers: monitor heart rate and blood pressure.
• NSAIDs: may attenuate antihypertensive response.
• Lipid‑lowering agents (e.g., statins metabolised by CYP3A4): watch for increased statin levels.